99 to 1.10 HGB .0061 0.92 0.86 to 0.98 .21 0.96 0.89 to 1.03 Primary tumor type? .61 1.06 0.84 to 1.35 .19 1.19 0.92 to 1.54 View it in a separate window Abbreviations: TTP, time to progression; HR, hazard ratio; WT, wild type; ANC, absolute neutrophil count; HGB, hemoglobin. *Treatment of imatinib 400 mg/d v 800 mg/d. Pazopanib FGFR ?Performance score of 0 to 1 v 2 to 3. ?Gastric v nongastric tumor type. Table A4. Univariate and Multivariate Analysis of Cofactors Associated With OS Cofactor Analysis of OS Univariate Multivariate P HR 95% CI P HR 95% CI KIT mutation Exon 9 .014 1.79 1.13 to 2.85 .002 2.28 1.36 to 3.84 WT .049 1.46 1.00 to 2.13 .0003 2.08 1.40 to 3.10 Treatment* .96 1.01 0.75 to 1.35 .65 1.07 0.79 to 1.46 Sex, male .035 1.39 1.02 to 1.87 .003 1.65 1.18 to 2.25 Age, by decades .00038 1.23 1.
09 to 1.39 .00006 1.28 1.14 to 1.45 Zubrod performance? 9 �� 10?13 3.63 2.55 to 5.17 8.6 �� 10?9 3.40 2.24 to 5.15 ANC 7.5 �� 10?9 1.16 1.11 to 1.23 .044 1.07 1.00 to 1.14 HGB 7.6 �� 10?5 0.84 0.77 to 0.92 .023 0.90 0.82 to 0.99 Primary tumor type? .65 1.07 0.79 to 1.46 .11 1.31 0.94 to 1.82 View it in a separate window Abbreviations: OS, overall survival; HR, hazard ratio; WT, wild type; ANC, absolute neutrophil count; HGB, hemoglobin *Treatment of imatinib 400 mg/d v 800 mg/d. ?Performance score of 0 to 1 v 2 to 3. ?Gastric v nongastric tumor type. Notes published online ahead of print at www.jco.org on October 27, 2008 Supported in part by Grants No. CA33601, CA04919, CA32291, CA27525, CA31946, CA32102, and CA77202 from the National Cancer Institute (NCI); by Grants No.
U01-CA70172-01 and N01-CM-17003 from the NCI; by a Veterans Affairs Merit Review Grant (M.H.); and by research funding from Novartis Pharmaceuticals. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute. Authors�� disclosures of potential conflicts of interest are found at the end of this article.
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms arising in the digestive tract (Miettinen et al. 1998; Steigen and Eide 2006). Such tumors arise predominantly in the stomach (50%) and small intestine (25%) but can be found throughout the gastrointestinal tract. The age of patients with GISTs range from young adults to older than 90 years of age, but peak incidence is at ~60 years of age.
Most GISTs express the protein kinase KIT, and its immunohistochemical marker CD117 is important for making the diagnosis (Miettinen and Lasota 2001; Fletcher et al. 2002) by excluding other soft tissue tumors such as leiomyomas, leiomyosarcomas, schwannomas, and inflammatory polyps. Accurate diagnosis and evaluation Batimastat of malignant risk is very important for the treatment of patients with GISTs. Standard treatment for localized GISTs is complete surgical resection.